Japan biotech firm keen on JVs with Indian firms
Facebook Twitter google+ RSS Feed

Japan biotech firm keen on JVs with Indian firms

By agencies   |   Tuesday, 26 April 2005, 07:00 Hrs
Printer Print Email Email
BANGALORE:Medibic, a Japanese biotechnology company supporting genomic-based drug discovery, is keen on expanding its presence in India through more partnerships.

The company also wants to further consolidate its existing partnership with the Bangalore-based Strand Genomics, a life sciences informatics company focused on software for drug discovery and development.

Yasuhiro Hashimoto, President and CEO of MediBic, said, "We met several Indian companies and would take a view about final partnership at the appropriate time." He declined to give the investment figures for tie-ups. Japan has a huge potential for Indian companies, as it has the second largest `ethical' drugs (non-over-the counter) market after the U.S., he said.

Hashimoto said that MediBic hopes to expand tie-ups with Indian companies to offer customized data analysis through bio-informatics solutions to Japanese pharma companies.

"We have many clients who are interested in getting data on cell functions for drug discovery," he said.

Write your comment now
Submit Reset
SPOTLIGHT